To predict the sensitivity to ICIs between low- and high-risk groups as classified by the GDPLichi model, we further examined immunotherapy-related markers such as tumor mutation burden (TMB), neoantigen, and expression of PDCD1 (PD-1), CD274 (PD-L1), and CTLA4. This evidence concerns the gene PDCD1 and neoplasm.